APM - Aptorum Group Limited
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.1500 |
| Open | 3.2000 |
| Bid | 3.0000 x 800 |
| Ask | 3.2500 x 800 |
| Day's Range | 3.0700 - 3.2002 |
| 52 Week Range | 1.6600 - 33.2800 |
| Volume | 8,128 |
| Avg. Volume | 34,407 |
| Market Cap | 95.414M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6440 |
| Earnings Date | Apr 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.00 |
Fair Value
Related Research
- Business Wire
Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update
Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced financial results for the fiscal year ended December 31, 2019, and provided a business update.
- Business Wire
Aptorum Group Limited to Present at the Infectious Disease Virtual Conference
Aptorum Group Limited (Nasdaq:APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, including orphan diseases, infectious diseases and metabolic diseases, today announced its participation at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020, 10:00 a.m. ET. Aptorum Group’s President and Executive Director Mr. Darren Lui will join a panel, which entitled "Non-antibiotic Anti-infectives." This panel is scheduled for 10:30 a.m. ET to 12:00 p.m. ET. To RSVP for the virtual conference, please click through: https://m-vest.com/insights/blog/Infectious-Disease-Virtual-Conference-2020
- ACCESSWIRE
Aptorum Group Limited to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020
NEW YORK, NY / ACCESSWIRE / April 15, 2020 / Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global ...
- Business Wire
Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provides an update on the Company’s operations in light of the recent declaration of the coronavirus outbreak as a pandemic declared by the World Health Organisation on March 11, 2020.
- Business Wire
Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Ian Huen, Chief Executive Officer and Executive Director, and Darren Lui, President and Executive Director, will present at the Solebury Trout Virtual Investor Conference on Thursday, April 2, at 12:00 pm ET. The conference will webcast at the Solebury Trout website (https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36519/indexl.html). The presentation length would be 25 minutes.
- Business Wire
Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACTâ„¢ Platform and Acticule Infectious Disease Platform
Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas, today announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and has also entered into agreement with the University of Hong Kong’s Microbiology Department to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies to initiate clinical trials on suitable candidates.
- ACCESSWIRE
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March ...
- Simply Wall St.
Did You Manage To Avoid Aptorum Group's (NASDAQ:APM) 13% Share Price Drop?
Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...
- Simply Wall St.
Aptorum Group Limited's (NASDAQ:APM) Single Biggest Risk For Investors
Trailing twelve-month data shows us that Aptorum Group Limited's (NASDAQ:APM) earnings loss has accumulated to...
- Zacks Small Cap Research
APM: Aptorum Focused on Development of Diseases with Significant Global Unmet Needs
Aptorum Group Limited (APM) went public through an initial public offering which closed in December 2018 and raised $12.0M (gross) from the sale of 761k common shares. The shares were added to the Morgan Stanley Capital International (MSCI) Hong Kong Micro Cap Index in May 2019. Aptorum is a Hong Kong based pre-revenue company focused on the development and eventual commercialization of a range of therapeutics in neurology, infectious diseases, gastroenterology, oncology and other disease areas.
